Hemogenyx Pharmaceuticals plc
(“Hemogenyx” or the “Company”)
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has been advised that Andrew Wright, the Company’s Financial Controller and Company Secretary (PDMR), purchased 257,069 ordinary shares of £0.01 each in the Company (“Ordinary Shares”) at a price of 1.945p per share. Following this transaction, Mr Wright now has a total beneficial interest in 1,097,405 Ordinary Shares, representing approximately 0.28 per cent of the Company’s issued share capital as enlarged by the placing announced on 30 January 2020.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|1.||Details of PDMR/person closely associated with them|
|b)||Position/status||Financial Controller and Company Secretary/PDMR (non-board)|
|2.||Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted|
|a)||Description of the financial instrument||Ordinary shares of 1p of Hemogenyx Pharmaceuticals plc
Identification code GB00BYX3WZ24
|b)||Nature of the transaction||Allotment of ordinary shares|
|c)||Price(s) and volume(s)||
– Aggregated volume
|e)||Date of the transaction||30-01-2020|
|f)||Place of the transaction||London Stock Exchange
|Hemogenyx Pharmaceuticals plc||hemogenyx.com|
|Dr Vladislav Sandler, Chief Executive Officer & Co-Founderfirstname.lastname@example.org|
|Sir Marc Feldmann, Chairman|
|SP Angel Corporate Finance LLP||Tel: +44 (0)20 3470 0470|
|Matthew Johnson, Vadim Alexandre, Soltan Tagiev|
|Peterhouse Corporate Finance Limited||Tel: +44 (0)20 7469 0930|
|Lucy Williams, Duncan Vasey|
|US Media enquiries||Tel: +1 (323) 646-3249|